The results of a Phase I study have been published in the journal Molecular Systems Biology describing the kinetics of the Combined Metabolic Cofactor Supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate. The study assessed the tolerability CMCS by first performing a 7-day rat toxicology study. Next, a human calibration study by supplementing CMCS and a control study was carried out to study the kinetics of these metabolites in the plasma of healthy subjects with and without supplementation. Clinical parameters have been measured and no immediate side effects have been observed. Moreover, plasma metabolomics and inflammatory protein markers data have been generated using the plasma of the patients and the acute changes associated with the supplementation of CMCS have been revealed. The data generated in the study has been integrated with the state-of-the-art systems biology methods developed and reported that the supplementation of CMCS significantly affects the global human lipid, amino acid, and antioxidant metabolism associated with NAFLD and other metabolism related diseases. The article was presented at the front cover of the journal.
